Market Access

Eli Lilly's acquisition of AtaiBeckley signals growing pharmaceutical industry commitment to psychedelic-based treatments for treatment-resistant depression.

In this week's Pharma Pulse, CVS Caremark settles with the FTC over rebates and TrumpRx, Germany more than doubles its drug rebate, and the FDA proposes a registration rule.

Many barriers to therapy emerge after a prescription is written. Karina Castagna makes the case for access support embedded at the point of care.

Germany's new health insurance law more than doubles mandatory drug rebates. Here is why it matters for US pharma pricing and launches.

RxLogic's Ann Beal on how PBM reform indirectly impacts pharma manufacturers' affordability programs, rebate planning, and patient access.

TailorMed and Tennr are integrating referral automation with medication affordability tools for infusion centers and specialty pharmacies, aiming to address patient barriers earlier.

As Medicare expands GLP-1 access, pharmacies emerge as key to adherence, through patient education, ongoing engagement and timely intervention

Trutakna's FDA approval for IgAN highlights how patient support programs like TRU SUPPORT coordinate access and adoption in specialty drug launches.

Partha Anbil and Partha Khot examine what makes patient support programs succeed, industry adoption trends, key criticisms, and the strategic path forward.

In the first half of this analysis, Partha Anbil and Partha Khot examine how patient support programs cut discontinuation and improve patient outcomes, reshaping hub services into an industry standard.

Generating real-world evidence isn't enough. What drives market access is whether payers can actually evaluate and act on it.

This week's Pharma Pulse covers the launch of Medicare's GLP-1 Bridge, FDA's approval of the first regulatory T-cell therapy for chronic GVHD, seven companies tapped for FDA's PreCheck manufacturing pilot, and a wave of dealmaking.

Amber Hussain Siddique explains why that inventory economics, FEFO compliance gaps, and freight cost structures are driving America's persistent drug shortage crisis and what it takes to fix it.

As hub transitions accelerate and digital tools reshape how support is delivered, four patient services experts weigh in on what's driving change in 2026, and what manufacturers need to get right to keep patients on therapy.

As PBM pressure mounts and formulary bidding wars squeeze manufacturers, a direct access marketplace model offers drug makers a path to compete on efficacy, price and real-world outcomes.

PwC's Philip Sclafani discusses oral GLP-1 cost exposure, oncology drug spend under the medical benefit, and his outlook on PBM reform.

PwC’s Philip Sclafani discusses rising payer cost exposure, GLP-1 growth, and why pharmacy spending is outpacing medical cost trend heading into 2027.

PwC projects drug spending will outpace medical trends in 2027, driven by GLP-1s and oncology. Here's what it means for market access.

In this week's Pharma Pulse, Europe’s drug pricing standoff intensifies, CMS moves to formalize Medicare negotiation rules, FDA expands OTC naloxone, and DSV launches a new pharma air route.

Behavioral and engagement insights are helping biopharma companies design more personalized patient support programs that improve persistence and long-term outcomes.

Will Shrank, MD, breaks down why payers, providers, and manufacturers are all struggling to keep pace with a rapidly expanding cell and gene therapy pipeline — and what it will take to fix it.

A new BGH survey shows some large employers are pulling back on GLP-1 weight-loss coverage in 2027 as rising costs and utilization outpace anticipated savings.

In this week's Pharma Pulse, USP's annual shortages report reveals a sharp rise in drug discontinuations, J&J and Roche commit billions to protein degrader platforms, and more.

As specialty drug spend tops 50% of pharmacy costs, health system specialty pharmacies are evolving from dispensers into longitudinal care management partners.

USP's Annual Drug Shortages Report reveals a sharp rise in product discontinuations, driven by unsustainable generic pricing, upstream geographic concentration, and manufacturing complexity.